Navigation Links
Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
Date:3/16/2010

SAN MARINO, Calif., March 16 /PRNewswire/ -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.

The advent of pathotropic (disease-seeking) targeting technology first enabled the development of  tumor-targeted Rexin-G, which seeks-out, accumulates-in, and selectively delivers a lethal designer gene to tumors that have spread throughout the body (metastatic cancer), halting the progression of disease while improving both survival and quality-of-life. Approved for all solid tumors in the Philippines, Rexin-G has received Orphan Drug and Fast Track status from the U.S. FDA, and is currently moving on to Phase III trials for first-line and second-line indications.  Once the control of tumor growth has been achieved with Rexin-G, the need to extend the treatment intervals and/or clinical remissions led to the development of Reximmune-C, a second tumor-targeted genetic medicine which delivers a pulse of immune-stimulating cytokine directly to the sites of residual or recurrent disease, thereby recruiting the patient's own immune system into the lesions of the residual cancer to invoke a more lasting anti-tumor immune response.

Much like a SWAT (special weapons and tactics) Team that calls an elite police force to the scene of a crime, Reximmune-C acts at the local level, recruiting the body's own professional immune cells, antigen-presenting cells, helper cells, and killer T-cells directly to the locus of the residual cancer, where tumor debris as antigens are abundant.  This provides the patient with an opportunity to mount a beneficial immune response that would further improve clinical outcome. Unlike, previous approaches to personalized cancer vaccination, a simple intravenous infusion of tumor-targeted Reximmune-C marshals the cadre of complex immunological responses of this intrinsic SWAT Team to the place where it is needed most.  By reaching beyond the boundaries of medicine to the very crux of metastatic disease, Epeius delivers another vital innovation.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.

To learn more about our pipeline of proprietary biotechnologies, please visit us at http://www.epeiusbiotech.com .

*(LOGO 72dpi: Send2press.com/mediaboom/09-1012-EpeiusBio_72dpi.jpg)  

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

SOURCE Epeius Biotechnologies

Back to top

RELATED LINKS
http://www.epeiusbiotech.com

'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
2. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
3. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
4. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
5. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
6. Watson Receives FDA Approval for Generic Cardizem(R) LA
7. ADVENTRX Receives Brand Name Acceptance for ANX-530
8. CEL-SCI Receives Payment From Marketing Partner
9. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
10. ISTA Pharmaceuticals Receives Action Date for FDA Review of Once-Daily XiDay(TM)
11. GelFix(TM) Posterior Spinal Distraction Implant Receives CE Mark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... known U.S. mesh product liability claims and that it ... U.S. claims at reasonable values. Under the agreements, Endo ... of 2017 and continuing through the fourth quarter of ... the Company intends to increase its mesh product liability ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon Dr. James Veltmeyer, ... announced his candidacy for the 52nd Congressional District currently held by Representative Scott Peters. ... to this country at age eleven after suffering homelessness and hardship in a distant ...
(Date:8/20/2017)... ... August 20, 2017 , ... A total solar eclipse will occur across ... minutes as the moon moves between the sun and Earth. This rare event will be ... tips can help keep you safe on the road during the total eclipse of the ...
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult ... If so, you may be interested in participating in a research study that ... research is to understand more about the relational aspects of adults who have gluten ...
(Date:8/19/2017)... , ... August 18, 2017 , ... ... aimed at creating a transparent, verifiable database to help the cannabis industry move ... technology, Paragon hopes to deliver a faster technology with lower fees. Paragon will ...
(Date:8/19/2017)... Toronto, ON (PRWEB) , ... August 19, 2017 , ... ... of the of NaturallyCurly.com® The Curl Leaders, Editors’ Choice 2017 Award for the second ... must-have accessory for hair stylists and curlies alike was voted Best Moisturizer for Type ...
Breaking Medicine News(10 mins):